Literature DB >> 32507831

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?

Takashi Nomiyama1.   

Abstract

Entities:  

Year:  2020        PMID： 32507831      PMCID： PMC7803835          DOI： 10.5551/jat.ED130

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN： 1340-3478            Impact factor:   4.928


× No keyword cloud information.
  10 in total

Review 1.  Cardiovascular outcome trials of the newer anti-diabetic medications.

Authors:  Tushar Acharya; Prakash Deedwania
Journal:  Prog Cardiovasc Dis       Date:  2019-08-21       Impact factor: 8.194

2.  Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).

Authors:  Takashi Nomiyama; Dai Shimono; Tsuyoshi Horikawa; Yuki Fujimura; Tomohiro Ohsako; Yuichi Terawaki; Takashi Fukuda; Ryoko Motonaga; Makito Tanabe; Toshihiko Yanase
Journal:  Endocr J       Date:  2018-05-26       Impact factor: 2.349

3.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

4.  Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.

Authors:  Byambasuren Ganbaatar; Daiju Fukuda; Masakazu Shinohara; Shusuke Yagi; Kenya Kusunose; Hirotsugu Yamada; Takeshi Soeki; Ken-Ichi Hirata; Masataka Sata
Journal:  Eur J Pharmacol       Date:  2020-02-27       Impact factor: 4.432

5.  Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.

Authors:  Yuichi Terawaki; Takashi Nomiyama; Takako Kawanami; Yuriko Hamaguchi; Hiroyuki Takahashi; Tomoko Tanaka; Kunitaka Murase; Ryoko Nagaishi; Makito Tanabe; Toshihiko Yanase
Journal:  Cardiovasc Diabetol       Date:  2014-11-19       Impact factor: 9.951

6.  The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice.

Authors:  Weiling Leng; Xinshou Ouyang; Xiaotian Lei; Mingxia Wu; Liu Chen; Qinan Wu; Wuquan Deng; Ziwen Liang
Journal:  Mediators Inflamm       Date:  2016-12-26       Impact factor: 4.711

7.  The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.

Authors:  Yusuke Nakatsu; Hiroki Kokubo; Batmunkh Bumdelger; Masao Yoshizumi; Takeshi Yamamotoya; Yasuka Matsunaga; Koji Ueda; Yuki Inoue; Masa-Ki Inoue; Midori Fujishiro; Akifumi Kushiyama; Hiraku Ono; Hideyuki Sakoda; Tomoichiro Asano
Journal:  Int J Mol Sci       Date:  2017-08-04       Impact factor: 5.923

8.  Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.

Authors:  Hiroyuki Takahashi; Takashi Nomiyama; Yuichi Terawaki; Takeshi Horikawa; Takako Kawanami; Yuriko Hamaguchi; Tomoko Tanaka; Ryoko Motonaga; Takashi Fukuda; Makito Tanabe; Toshihiko Yanase
Journal:  Biochem Biophys Rep       Date:  2019-04-19

9.  Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice.

Authors:  Arief Rahadian; Daiju Fukuda; Hotimah Masdan Salim; Shusuke Yagi; Kenya Kusunose; Hirotsugu Yamada; Takeshi Soeki; Masataka Sata
Journal:  J Atheroscler Thromb       Date:  2020-02-26       Impact factor: 4.928

10.  GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells.

Authors:  Hiroyuki Takahashi; Takashi Nomiyama; Yuichi Terawaki; Takako Kawanami; Yuriko Hamaguchi; Tomoko Tanaka; Makito Tanabe; Dennis Bruemmer; Toshihiko Yanase
Journal:  J Atheroscler Thromb       Date:  2018-06-30       Impact factor: 4.928
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.